SOAT1 and granuloma annulare: Clinical evidence indicates that the use of JAK inhibitors, such as upadacitinib and abrocitinib, can effectively block this signaling axis and significantly improve GA skin lesions, thereby providing therapeutic confirmation of the central role of the JAK-STAT pathway in the pathogenesis of granuloma annulare (70–72).